• 1
    Centers for Disease Control and Prevention. 2007 National diabetes fact sheet. Accessed November 13, 2010.
  • 2
    Center for Disease Control and Prevention. SEARCH for Diabetes in Youth. Accessed November 13, 2010.
  • 3
    Pettitt DJ, Sand MR, Bennett PM, et al. Familial predisposition to renal disease in two generations of Pima Indians with type II (non-insulin dependent) diabetes mellitus. Diabetologia. 1990;33:438.
  • 4
    Mein CA, Caulfield MJ, Dobson RJ, et al. Genetics of essential hypertension. Hum Mol Genet. 2004;13(Spec No 1):R169R175.
  • 5
    Greene DA, Lattimer SA, Sima AAF. Sorbitol, phosphoinosotides, and sodium-potassium ATPase in the pathogenesis of diabetic complications. N Engl J Med. 1987;316:599.
  • 6
    Brownlee M. Banting Lecture 2004: the pathobiology of diabetic complications – a unifying mechanism. Diabetes. 2005;54:1615.
  • 7
    Viassara H. Receptor-mediated interaction of advanced glycosylation end products with cellular components within diabetic tissues. Diabetes. 1992;41(suppl 2):52.
  • 8
    Hostestter TH. Diabetic nephropathy, metabolic versus hemodynamic considerations. Diabetes Care. 1992;15:1205.
  • 9
    Sharp PS. Growth factors in the pathogenesis of diabetic retinopathy. Diabetes Rev. 1995;3:164.
  • 10
    Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med. 1993;328:1676.
  • 11
    Dagogo-Jack S, Santiago JV. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions. Arch Intern Med. 1997;157:1802.
  • 12
    Ayerden EF, Haksun E Ulver DB, Ulver DB. The relationship between vascular endothelial growth factor (VEGF) and microalbuminuria in patients with essential hypertension. Intern Med. 2008;47(17):15111516.
  • 13
    Park JB, Schiffrin EL. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertens. 2001;19:921930.
  • 14
    Dagogo-Jack S. Primary prevention of cardiovascular disease in diabetic patients. Cardio Q. 2006;12:20.
  • 15
    Nesto RW. Correlation between cardiovascular disease and diabetes mellitus: current concepts. Am J Med. 2004;116:11S.
  • 16
    Nathan DR, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. N Engl J Med. 2005;353:2643.
  • 17
    Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577.
  • 18
    Ceriello A, Ihnat MA, Thorpe JE. The ‘metabolic memory’: is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab. 2009;94:410415.
  • 19
    Ceriello A. Hyperglycemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes. Eur J Cardiovasc Prev Rehabil. 2010;17(1):S15S19.
  • 20
    Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000;36:646.
  • 21
    Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA. 1982;248(12):14651477.
  • 22
    Juutilianen A, Lehto S, Ronnemaa T, et al. Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects. Diabetes Care. 2005;28(12):29012907.
  • 23
    Hypertension in Diabetes Study Investigators. Hypertension in Diabetes Study (HDS): II, increased risk of cardiovascular complications in hypertensive type 2 diabetes patients. J Hypertens. 1993;11:319325.
  • 24
    Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281:1291.
  • 25
    Khaw KT, Wareham N, Bingham S, et al. Association of hemoglobin A1C with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004;141:413.
  • 26
    Congdon NG, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA. 2003;290:20572060.
  • 27
    Varma R. From a population to patients: the Wisconsin epidemiologic study of diabetic retinopathy. Ophthalmology. 2008;115:18571858.
  • 28
    Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension. 1995;26(6):869879.
  • 29
    The National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension. 1994;23:145158.
  • 30
    Myers BD. Pathophysiology of proteinuria in diabetic glomerular disease. J Hypertens. 1990;8:S41S46.
  • 31
    The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med. 1993;329:977986.
  • 32
    Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225.
  • 33
    Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):22852293.
  • 34
    UK Prospective Diabetes Study Group. UK Prospective Diabetes Study VIII: study design, progress and performance. Diabetologia. 1991;34:877.
  • 35
    American Diabetes Association. Standards of medical care in diabetes – 2010. Diabetes Care. 2009;33:S11S61.
  • 36
    Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowing in type 2 diabetes. New Engl J Med. 2008;358:2545.
  • 37
    ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New Engl J Med. 2008;358:2560.
  • 38
    Duckworth W, Abraira C, Moritz T, et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129.
  • 39
    de Boer IH, Kestenbaum B, Rue TC, et al. Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. Arch Intern Med. 2008;168(17):18671873.
  • 40
    UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703.
  • 41
    Estacio RO, Jeffers BW, Gifford N, et al. Effects of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23:B54.
  • 42
    Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy, and stroke. Kidney Int. 2002;61:1086.
  • 43
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of Hypertension-Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755.
  • 44
    ACCORD Study Group. Effects of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):15751585.
  • 45
    Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Blood Pressure Lowering Treatment Trialists’ Collaboration. Arch Intern Med. 2005;165:1410.
  • 46
    Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417.
  • 47
    Patel A, ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829.
  • 48
    Diabetes Prevention Research Group. Impact of intensive lifestyle and metformin on cardiovascular risk factors in the diabetes prevention program (DPP). Diabetes Care. 2005;28(4):888894.
  • 49
    Kong C, Nimmo L, Elatrozy T, et al. Smoking is associated with increased hepatic lipase activity, insulin resistance, dyslipidemia and early atherosclerosis in type 2 diabetes. Atherosclerosis. 2001;156:373.
  • 50
    Ranney L, Melvin C, Lux L, et al. Systematic review: smoking cessation intervention strategies for adults and adults in special populations. Ann Intern Med. 2006;145:845856.
  • 51
    Katzmarzyk PT, Church TS, Blair SN. Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med. 2004;164:1092.
  • 52
    Estruch R, Martinez-Gonzalez MA, Corella D, et al. Effects of a Mediterranean-style diet on cardiovascular risk factors. A randomized trial. Ann Intern Med. 2006;145:1.
  • 53
    Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA. 2004;292:1433.
  • 54
    Beretta-Piccoli C, Weidmann P. Body sodium-blood volume state in nonazotemic diabetes mellitus. Miner Electrolyte Metab. 1982;7:3647.
  • 55
    DeFronzo RA. The effect of insulin on renal sodium metabolism. A review with clinical implications. Diabetologia. 1981;21:165171.
  • 56
    Aoi N, Soma M, Nakayama T, et al. Variable number of tandem repeat of the 5′-flanking region of type-C human natriuretic peptide receptor gene influences blood pressure levels in obesity-associated hypertension. Hypertens Res. 2004;27:711716.
  • 57
    Gaede P, Lund-Andersen H, Parving HH, et al. Effects of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580591.
  • 58
    Knopp RH, d’Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:14781485.
  • 59
    Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systemic review. JAMA. 2007;298:7861485.
  • 60
    Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long term benefit with niacin. J Am Coll Cardiol. 1986;8:12451255.
  • 61
    Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410418.
  • 62
    Expert Panel of Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:24872497.
  • 63
    Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thromobolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:14951504.
  • 64
    deLemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:13071316.
  • 65
    Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effects of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:10711080.
  • 66
    Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute. American College of Cardiology Foundation, American Heart Association. Implications of recent trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227239.
  • 67
    Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risks: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31:811822.
  • 68
    Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet. 2009;373:18491860.
  • 69
    Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):21952207.